- Journal List
- Acta Neuropathol Commun
- v.11; 2023
- PMC10594904
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Acta Neuropathol Commun. 2023; 11: 170.
Published online 2023 Oct 24. doi:10.1186/s40478-023-01667-x
PMCID: PMC10594904
PMID: 37875973
Arnault Tauziède-Espariat,
1 Emmanuelle Uro-Coste,2,3,4 Yvan Nicaise,3 Philipp Sievers,5,6 Andreas von Deimling,5,6 Felix Sahm,5,6 Oumaima Aboubakr,1 Alice Métais,1,7 Fabrice Chrétien,1 and Pascale Varlet1,7
Author information Article notes Copyright and License information PMC Disclaimer
Associated Data
- Supplementary Materials
- Data Availability Statement
Diffuse pediatric-type high-grade glioma (pHGG), IDH- and H3-wildtype are currently subdivided into three subgroups: pHGG-RTK (Receptor Tyrosine Kinase) 1, pHGG-RTK2, and pHGG-MYCN [2]. Each subgroup is known to present recurrent gene amplifications such as PDGFRA, EGFR and MYCN, respectively for RTK1, RTK2, and MYCN [2] but these amplifications are not specific to these subgroups. Although recurrent histopathological (such as nodules composed of large cells with prominent nucleoli and expression of glial and neuronal markers) [4, 5], and genetic (TP53 mutations, particularly in a context of Li-Fraumeni syndrome) features [1] have been identified in pHGG-MYCN, the diagnosis of this subgroup is currently confirmed only by DNA-methylation analysis. Because a subset of pHGG-MYCN have been found to harbor an amplification of the ID2 gene with (12/36, 33%) or without (1/36, 3%) a concomitant MYCN amplification (MYCN+/ID2+) [2], we have formulated a FISH (Fluorescence in situ hybridization) technique that targets both loci. Taking a monocentric series of 29 pHGG, IDH- and H3-wildtype, we studied the status of MYCN and ID2 for each tumor, and correlated the data with histopathological and genetic features (including TP53 status, somatic and germline), and DNA-methylation profiling.
The results are detailed in Supplementary Fig.1 and Supplementary Table1. The integrative histopathological, genetic and epigenetic analyses, including t-Distributed Stochastic Neighbor Embedding analysis (t-SNE) (Supplementary Fig.2) segregated tumors into: pHGG-RTK1 (n = 5), pHGG-RTK2 (n = 11), and pHGG-MYCN (n = 13). All DNA-methylation proven pHGG-MYCN, except one (#11), harbored an amplification of MYCN, and five of them an ID2 amplification (Fig.1). A MYCN amplification was also observed in 31% (5/16) of pHGG-non MYCN (four RTK2 and one RTK1). However, none of them had an ID2 amplification. Ten/13 pHGG-MYCN presented the histopathological features previously reported for this subgroup, whereas the three remaining cases showed features typically associated with diffuse astrocytic gliomas. Somatic mutations of TP53 were present in 12/13 pHGG-MYCN, and four of them (with available data) harbored a germline mutation (Fig.1). The outsider case (#11) presented the histopathological features of pHGG-MYCN, a TP53 somatic mutation and a MYC amplification (Supplementary Fig.3).
Fig.1
Histopathological and molecular features of pediatric high-grade gliomas, MYCN subgroup. The case #3 presented classical features of HGG-MYCN such as a dense proliferation composed of large cells with prominent nucleoli (HPS, magnification x400) with overexpression of p53 (magnification x400). The FISH analysis evidenced an amplification of both MYCN (orange signals) and ID2 (blue signals) loci (magnification x800). There was no Li-Fraumeni syndrome in this case. The case #7 presented classical features of HGG-MYCN such as a dense proliferation composed of large cells with prominent nucleoli and numerous mitoses (HPS, magnification x400) with overexpression of p53 (magnification x400). The FISH analysis evidenced an amplification of MYCN locus without amplification of ID2 gene (magnification x800). There was a context of Li-Fraumeni syndrome. FISH: Fluorescence in situ hybridization; HGG: high-grade glioma; HPS: Hematoxylin Phloxin Saffron; mut.: mutation. Black scale bars represent 50μm
As previously reported [2], a subset of pHGG-MYCN presented a co-amplification of MYCN and ID2 (MYCN+/ID2+), which was specific for this subgroup of pHGG, and another subset of pHGG harbored an amplification of MYCN without ID2 amplification (MYCN+/ID2-). The current series showed that all pHGG-MYCN cases, except one, harbored a somatic TP53 mutation and a subset of them presented a germline mutation for TP53, as previously reported [1]. Interestingly, our results seem to show that pHGG-MYCN MYCN+/ID2 + are not associated with TP53 germline mutations, whereas Li-Fraumeni syndrome is present in the subgroup of MYCN+/ID2-. Moreover, the current series described for the first time a pHGG-MYCN without amplifications of MYCN and ID2 but harboring a MYC amplification. This example may illustrate the phenomenon previously described where a spinal ependymoma classified as “MYCN amplified” by DNA-methylation profiling but harbored a MYC amplification [3]. DNA-methylation analysis is still only limited to a small number of centres worldwide or may not be contributive (8/29 cases from this cohort presented a low calibrated score for a methylation class), so alternative methods for routine practice need to be validated. Therefore, histopathology (including p53 overexpression correlated to TP53 mutation), and FISH MYCN/ID2 may help diagnose pHGG-MYCN, using a simple algorithm approach (Fig.2).
Fig.2
Diagnostic approach for pediatric high-grade glioma, with MYCN-amplification. Co-amp.: co-amplification; HGG: high-grade glioma; LFS: Li-Fraumeni syndrome; ped: pediatric; Wt: wildtype. Black scale bars represent 50μm
While a subset of pHGG-MYCN is found in the tumoral spectrum of Li-Fraumeni syndrome, for exclusion purposes, the co-amplication MYCN/ID2 seems not to be associated with this genetic predisposition. The association of histopathological and genetic features may potentially represent alternative diagnostic criteria for pHGG-MYCN, particularly if DNA-methylation profiling is not available or not conclusive. FISH analyses of MYCN/ID2 genes may constitute an interesting diagnostic tool for routine neuropathological practice.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Material 1: Figure S1. Clinical, histopathological, genetic and epigenetic characteristics of the cohort.(69K, tif)
Supplementary Material 2: Figure S2. t-distributed stochastic neighbor embedding (t-SNE) analysis of DNA methylation profiles of the investigated tumors alongside selected reference samples. Reference DNA methylation classes: diffuse midline glioma H3 K27M mutant (DMG_K27); diffuse midline glioma EGFR-altered (DMG_EGFR); diffuse high-grade glioma, H3.3 G34 mutant (GBM_ G34); pediatric glioblastoma, IDH wildtype, subclass MYCN (GBM_pedMYCN); pediatric glioblastoma, IDH wildtype, subclass RTK1a (GBM_pedRTK1a); pediatric glioblastoma, IDH wildtype, subclass RTK1b (GBM_pedRTK1b); pediatric glioblastoma, IDH wildtype, subclass RTK1c (GBM_pedRTK1c); pediatric glioblastoma, IDH wildtype, subclass RTK2a (GBM_pedRTK2a); pediatric glioblastoma, IDH wildtype, subclass RTK2b (GBM_pedRTK2b).(917K, tif)
Supplementary Material 3: Figure S3. Histopathological and molecular features of the case #11. The case #11 presented classical features of HGG-MYCN such as a dense proliferation composed of large cells with prominent nucleoli (HPS, magnification x400) with overexpression of p53 (magnification x400). The FISH analysis failed to reveal any amplification of MYCN and ID2 loci, but there was an amplification of MYC gene (green signals, orange signals: centromere of chromosome 8) (magnification x800). There was no germline mutation of TP53. FISH: Fluorescence in situ hybridization; HGG: high-grade glioma; HPS: Hematoxylin Phloxin Saffron; mut.: mutation. Black scale bars represent 50μm.(12M, tif)
Supplementary Material 4: Detailed clinical, histopathological, genetic and epigenetic characteristics of the cohort.(14K, xlsx)
Acknowledgements
We are thankful for the laboratory technicians at GHU Paris Neuro Sainte-Anne Hospital for their assistance.
Authors’ contributions
ATE, YN and EUC participated in conception, design, collection and assembly of data. ATE, FC, OA, AME and PV conducted the neuropathological examinations. PS, AVD and FS conducted the molecular analyses. ATE drafted the manuscript. All authors reviewed the manuscript and approved the final version.
Funding
No funding.
Availability of data and material
Not applicable.
Declarations
Competing interests
The authors declare that they have no conflicts of interest directly related to the topic of this article.
Ethics approval
This study was approved by the local ethical committees from GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, and Necker Enfants Malades Hospital. Informed consent was obtained specifically from each patient/family for the constitutional genetic study.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Guerrini-Rousseau L, Tauziède-Espariat A, Castel D, Rouleau E, Sievers P, Saffroy R, Beccaria K, Blauwblomme T, Hasty L, Bourdeaut F, Grill J, Varlet P, Debily M-A. Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome. Acta Neuropathol Commun. 2023;11:3. doi:10.1186/s40478-022-01490-w. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Korshunov A, Schrimpf D, Ryzhova M, Sturm D, Chavez L, Hovestadt V, Sharma T, Habel A, Burford A, Jones C, Zheludkova O, Kumirova E, Kramm CM, Golanov A, Capper D, von Deimling A, Pfister SM, Jones DTW. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol (Berl) 2017;134:507–516. doi:10.1007/s00401-017-1710-1. [PubMed] [CrossRef] [Google Scholar]
3. Shatara M, Schieffer KM, Klawinski D, Thomas DL, Pierson CR, Sribnick EA, Jones J, Rodriguez DP, Deeg C, Hamelberg E, LaHaye S, Miller KE, Fitch J, Kelly B, Leraas K, Pfau R, White P, Magrini V, Wilson RK, Mardis ER, Abdelbaki MS, Finlay JL, Boué DR, Cottrell CE, Ghasemi DR, Pajtler KW, Osorio DS. Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas. Acta Neuropathol Commun. 2021;9:192. doi:10.1186/s40478-021-01296-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Tauziède-Espariat A, Debily M-A, Castel D, Grill J, Puget S, Roux A, Saffroy R, Pagès M, Gareton A, Chrétien F, Lechapt E, Dangouloff-Ros V, Boddaert N, Varlet P. The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts. Acta Neuropathol Commun. 2020;8:104. doi:10.1186/s40478-020-00974-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Tauziède-Espariat A, Debily M-A, Castel D, Grill J, Puget S, Sabel M, Blomgren K, Gareton A, Dangouloff-Ros V, Lechapt E, Boddaert N, Varlet P. An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN) Acta Neuropathol Commun. 2019;7:87. doi:10.1186/s40478-019-0738-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Articles from Acta Neuropathologica Communications are provided here courtesy of BMC
